Publication | Open Access
Serum miR-4530 sensitizes breast cancer to neoadjuvant chemotherapy by suppressing RUNX2
20
Citations
24
References
2018
Year
Our results revealed that elevated serum miR-4530 levels may sensitize breast cancer to taxane- and anthracycline-based NAC by suppressing RUNX2; therefore, this miRNA has the potential to be a new biomarker for predicting breast cancer chemosensitivity.
| Year | Citations | |
|---|---|---|
2015 | 11.9K | |
2004 | 10.8K | |
2011 | 2.7K | |
1998 | 2.2K | |
2011 | 1.9K | |
1997 | 1.8K | |
2008 | 1.7K | |
2001 | 1.3K | |
2010 | 332 | |
2005 | 325 |
Page 1
Page 1